A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
In a phase 2 trial, a regimen of gemcitabine plus eribulin compared favorably with other regimens for the first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma.
Patients who undergo surgical resection of nonmetastatic upper tract urothelial carcinoma with isolated lymph node involvement have a 5-year overall survival rate of only 24%, a study found.
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
In a study of men with Gleason 8 to 10 prostate cancer and low PSA, radical prostatectomy was associated with better survival odds than external beam radiation therapy with or without brachytherapy.
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
